Pure Global

Living Well With Lymphoma - Trial NCT06047626

Access comprehensive clinical trial information for NCT06047626 through Pure Global AI's free database. This phase not specified trial is sponsored by University of Michigan Rogel Cancer Center and is currently Not yet recruiting. The study focuses on Lymphoma. Target enrollment is 68 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.

Free Database
Powered by Pure Global AI
840K+ Trials
NCT06047626
Not yet recruiting
other
Trial Details
ClinicalTrials.gov โ€ข NCT06047626
View on ClinicalTrials.gov
Pure Global
DJ Fang

DJ Fang

MedTech Regulatory Expert

Need help with 30+ markets registration?

Pricing
Living Well With Lymphoma
Living Well With Lymphoma: Improving Diet Quality to Improve Energy, Sleep and Quality of Life

Study Focus

Lymphoma

Fatigue Reduction Diet

Interventional

other

Sponsor & Location

University of Michigan Rogel Cancer Center

Timeline & Enrollment

N/A

Dec 01, 2023

Apr 01, 2028

68 participants

Primary Outcome

Brief Fatigue Inventory

Summary

In this study the investigators are proposing to evaluate the efficacy, sustainability, and
 mechanisms of 3 months of individualized counseling of the FRD delivered by registered
 dietitians, over 8 sessions by phone/video conferencing on fatigue, quality of life, and
 associated symptoms in persistently fatigued lymphoma cancer survivors compared to 3 months
 of individualized counseling of the attention control (matched for time and frequency of
 interactions with the FRD) the General Health Curriculum (GHC). The investigators will
 randomize and follow 68 lymphoma cancer survivors; accounting for a ~10% drop out rate to
 achieve a target of 60 patients that will complete the study. The investigators hypothesize
 that persistently fatigued lymphoma cancer survivors will experience improvements in fatigue,
 quality of life, and symptoms commonly associated with fatigue, which are then maintained at
 15-months post-enrollment; and decreased CRP and alterations in inflammation-associated DNA
 methylation consistent with reduced inflammation from following the FRD as compared to the
 GHC.

ICD-10 Classifications

Hodgkin lymphoma
Follicular lymphoma
Non-Hodgkin lymphoma, unspecified
Follicular lymphoma, unspecified
Hodgkin lymphoma, unspecified

Data Source

ClinicalTrials.gov

NCT06047626

Non-Device Trial